Similarly, future trials may integrate TCEs into the upfront management of metastatic hormone-sensitive PCa (e.g., adding a TCE to ADT and AR inhibitors in high-risk patients) to determine whether it can deliver deeper responses. This evidence concerns the gene AR and posterior cortical atrophy.